NCT00378534View on ClinicalTrials.gov

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Chronic Myelogenous LeukemiaAcute Myelogenous LeukemiaChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
Interventions
DEVICE

Miltenyi reagent system

Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back

DRUG

Fludarabine

Therapeutic

DRUG

Cyclosporine

Therapeutic

DRUG

Cyclophosphamide

Therapeutic

OTHER

FILGRASTIM (G-CSF)

An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00378534 - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | Biotech Hunter | Biotech Hunter